- Design
- Population-level observational analysis of national datasets
- Population
- Benzodiazepine prescribing and ADR reports in England, 2020–2025
- Primary outcome
- Prescribing trends, costs and fatality ratios
- Effect
- −4.3% per year (95% CI −4.5 to −4.0); clobazam +6.4% per year
A population-level study in the British Journal of Clinical Pharmacology analysed national prescribing, cost and adverse-reaction data for 14 benzodiazepines in England. Prescribing fell from about 15 560 to 12 280 items per 100 000 population between 2020 and 2025, a mean decline of 4.3% a year, mostly through less diazepam, temazepam and chlordiazepoxide. Clobazam rose by about 6% a year.
Across spontaneous adverse-reaction reports, there were on average 4.5 deaths per 100 reported cases, with oxazepam, lorazepam and alprazolam highest. Deprivation and ethnicity were associated with differences in prescribing.
The fatality ratios come from voluntary reports and cannot be read as true death rates; they reflect who is prescribed each drug and what gets reported. The broader message — that sustained deprescribing policy can shift practice — is relevant in India, where alprazolam and clonazepam are widely available and often continued without review.
- Review long-term benzodiazepine prescriptions and offer a planned taper where appropriate.
- Prefer non-drug treatments for insomnia and anxiety as first line.
- Avoid combining benzodiazepines with opioids or alcohol.
- Fatality ratios from spontaneous reports are not comparable drug-to-drug risk estimates.
Why it matters
Benzodiazepine dependence is largely made in clinic, and can be unmade there.
Don't overread it
Deaths per reported case come from spontaneous reports; they do not show one benzodiazepine is more dangerous than another.
The statistics, in plain English
A fatality ratio is deaths divided by reported adverse-reaction cases, not by patients treated. Because serious events are more likely to be reported, these ratios overstate risk and are skewed by who receives each drug.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free